LLY logo Eli Lilly and Company +
Eli Lilly and Company
+

Eli Lilly and Company (LLY) Business News

Track Eli Lilly and Company in real time with a live news feed covering Eli Lilly and Company stock news, official press releases, company announcements, and an archive of historical Eli Lilly and Company news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

The Motley Fool

2:00 PM | Saturday | Aug 15, 2026

news photo
Loading...

Eli Lilly has a broad pipeline of weight-loss products that will help it maintain its lead in this area. The company should continue posting excellent financial results over the medium term.

Read full article redirect
2:00 PM | Saturday | Aug 15, 2026

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

The Motley Fool

Eli Lilly has a broad pipeline of weight-loss products that will help it maintain its lead in this area. The company should continue posting excellent financial results over the medium term.

Read full article arrow
News Thumbnail
2:00 PM | Saturday | Aug 15, 2026

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

The Motley Fool

Eli Lilly has a broad pipeline of weight-loss products that will help it maintain its lead in this area. The company should continue posting excellent financial results over the medium term.

Read full article arrow
News Thumbnail
10:51 AM | Friday | Aug 14, 2026

3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold

Zacks Investment Research

In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.

Read full article arrow
News Thumbnail
7:15 AM | Friday | Aug 14, 2026

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fool - Investing News

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

Read full article arrow
News Thumbnail
6:01 AM | Thursday | Aug 13, 2026

Novo CEO says obesity market won't be winner-take-all battle with Lilly

Reuters

Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, ‌and that new treatment options like pills will keep it from becoming a winner-take-all battle with rival Eli Lilly.

Read full article arrow
News Thumbnail
12:15 PM | Wednesday | Aug 12, 2026

I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)

Seeking Alpha

I underestimated Eli Lilly and Company. LLY's Retatrutide showed promising efficacy in TRIUMPH-2/TRIUMPH-3 trials, and if approved by the FDA, I believe it could become the "gold standard" in the obesity market. Meanwhile, Jaypirca generated $192 million in sales for Eli Lilly in Q2, up 56.4% year-on-year, despite competitive pressure from AstraZeneca's Calquence and BeOne Medicines' Brukinsa.

Read full article arrow
News Thumbnail
9:07 AM | Wednesday | Aug 12, 2026

Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide

Market Watch

Some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits for access to compounded versions of retatrutide.

Read full article arrow
News Thumbnail
7:39 AM | Wednesday | Aug 12, 2026

Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs

WSJ

Eli Lilly has filed six new lawsuits against U.S. entities that it alleges are selling a version of the company's investigational weight-loss drug on the black market.

Read full article arrow
News Thumbnail
5:32 AM | Wednesday | Aug 12, 2026

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

Reuters

Eli Lilly on Wednesday said it ‌had filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide, escalating its campaign against unauthorized sellers before the medicine has won regulatory approval.

Read full article arrow
News Thumbnail
5:30 AM | Wednesday | Aug 12, 2026

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

PRNewsWire

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors and shipping and logistics carriers—to help protect patients and fight this illicit activity.

Read full article arrow
News Thumbnail
11:00 AM | Tuesday | Aug 11, 2026

Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run

24/7 Wall Street

Eli Lilly (NYSE:LLY | LLY Price Prediction) delivered a monster quarter with revenue growth, a fourth consecutive EPS beat, and a fresh guidance raise.

Read full article arrow
News Thumbnail